Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) have been given a consensus rating of "Buy" by the six brokerages that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $9.50.
QNCX has been the topic of a number of recent analyst reports. Maxim Group initiated coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They set a "buy" rating and a $6.00 price target on the stock. Brookline Capital Management assumed coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They issued a "buy" rating and a $9.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and set a $12.00 target price on shares of Quince Therapeutics in a research note on Thursday. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 22nd. Finally, RODMAN&RENSHAW upgraded Quince Therapeutics to a "strong-buy" rating in a research report on Tuesday, October 29th.
Get Our Latest Report on QNCX
Hedge Funds Weigh In On Quince Therapeutics
An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC lifted its stake in Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) by 24.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 339,125 shares of the company's stock after buying an additional 66,170 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 30.75% of the company's stock.
Quince Therapeutics Stock Performance
Shares of Quince Therapeutics stock traded up $0.01 during trading on Thursday, hitting $1.88. 85,122 shares of the company's stock traded hands, compared to its average volume of 230,928. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The business has a 50-day simple moving average of $1.77 and a 200-day simple moving average of $1.09. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $82.72 million, a P/E ratio of -1.52 and a beta of 0.74.
Quince Therapeutics Company Profile
(
Get Free ReportQuince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
See Also
Before you consider Quince Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quince Therapeutics wasn't on the list.
While Quince Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
